0JDB.L - Invitae Corporation
| Previous close | 1.0687 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 38,170 |
| Market cap | 956,399 |
| Beta (5Y monthly) | 1.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0560 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireInvitae to Present at the William Blair 43rd Annual Growth Stock Conference
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 12:40 p.m. Central Time.
- PR Newswire
New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology
Invitae (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 2-6, 2023. The new research insights highlight innovations in genetic testing in a variety of clinical settings, population groups and cancer types, and reinforce the need to reduce barriers to genetic services to help patients receive the most effective care and monitoring.
- PR Newswire
Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. The Company has initiated a search for a new CFO. Ms. Wen will continue in her role through the end of the second quarter. Christine Gorjanc, the Company's longtime Chair of the Audit Committee of the Board of Directors, will assist during the transition and will assume the role of interim CFO, effective
- PR Newswire
Invitae to Appeal Trial Verdict
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the District of Delaware. The jury found that Invitae's products using Anchored Multiplex PCR ("AMP") chemistry infringe certain Natera, Inc. patents. The jury awarded Natera a total of $19.35 million, based on lost profits and a royalty rate of 10% on certain products. Invitae will vigorously defend itself in future proceedin
Motley FoolCathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood as an investor reminds me of the protagonists in the tornado-chasing classic Twister. The co-founder, CEO, and main stock picker of Ark Invest was active in the market windstorm on Wednesday, and thankfully for us, she posts her daily transactions at the end of every trading day. Wood added to her positions in Twilio (NYSE: TWLO), Palantir (NYSE: PLTR), and Invitae (NYSE: NVTA) on Wednesday.
Motley FoolInvitae (NVTA) Q1 2023 Earnings Call Transcript
Joining us today are president and CEO, Ken Knight; our CFO, Roxi Wen and our chief science officer, Dr. Robert Daber. Before we begin, I'd like to remind you that various remarks that we make on this call that are not historical includes those about our vision and business model, the company's strategic business realignment, future financial and operating results; expectations of future growth and reduction in burn rates, and future products, services of our product pipeline and the timing.
ZacksInvitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates
Invitae (NVTA) delivered earnings and revenue surprises of 9.76% and 1.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Invitae Reports First Quarter 2023 Financial Results
Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2023.
- PR Newswire
Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.
Motley FoolWhy Shares of Invitae Soared on Friday
Shares of Invitae Corporation (NYSE: NVTA) closed 11.57% higher on Friday after Cathie Wood, the CEO of Ark Invest, said the stock was undervalued. Wood's Ark Innovation ETF owns more than 18 million shares of Invitae, worth roughly $24 million as of Friday, so her company has a huge stake in the stock, which has declined more than 74% over the past year and more than 27% so far this year. Invitae specializes in genetic testing to improve healthcare outcomes.
- PR Newswire
Invitae Publishes Annual Environmental, Social and Governance (ESG) Report
Invitae (NYSE: NVTA), a leading medical genetics company, today published its 2023 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and our performance and progress through measurable data and metrics during the 2022 fiscal year.
- PR Newswire
New Study Findings Published in Nature Show Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier In Non-Small Cell Lung Cancer
Invitae (NYSE: NVTA), a leading medical genetics company, today announced new research published in Nature describing the first use of the company's personalized cancer monitoring (PCM) platform to demonstrate the utility of ctDNA as a biomarker for cancer recurrence in a large cohort of patients with stage I-III non-small-cell lung cancer (NSCLC) followed for up to five years.
Simply Wall St.Invitae Corporation (NYSE:NVTA) is a favorite amongst institutional investors who own 68%
Key Insights Significantly high institutional ownership implies Invitae's stock price is sensitive to their trading...
- PR Newswire
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
Invitae (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company, a healthcare investment firm, today announced a partnership to advance genetics-based drug discovery and development in rare disease. The partnership will leverage genetics and clinical data from millions of patients and Deerfield's broad drug discovery and development expertise.
- PR Newswire
Invitae Announces Partnership with Epic to Streamline Genetic Testing
Invitae (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company.
- PR Newswire
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of W. Michael Korn, M.D., as its chief medical officer for oncology, effective March 13, 2023. Dr. Korn brings decades of experience in the field of gastrointestinal cancers, implementing precision oncology principles in clinical cancer care, and designing a novel database on targeted cancer therapeutics.
- PR Newswire
Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing
Invitae (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be presented at the 2023 American Clinical Genetics Meeting held in Salt Lake City from March 14-18, 2023. The research reinforces the importance of universal genetic testing for patients with cancer, with much of the data highlighting the need for increased representation in clinical genetic testing data across racial, ethnic and ancestry groups that have
- PR Newswire
Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California. The policy, effective as of March 1, 2023, considers the test medically necessary for patients with stage I-IV cancer after surgical intervention for adjuvant or targeted therapy and/or monitoring for relapse or prog
- PR Newswire
Invitae to Present at the TD Cowen 43rd Annual Health Care Conference
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will participate in a fireside chat at the TD Cowen 43rd Annual Health Care Conference on Monday, March 6, at 1:30 p.m. Eastern.
- Motley Fool
Invitae (NVTA) Q4 2022 Earnings Call Transcript
Joining us today are president and CEO, Ken Knight; and our CFO, Roxi Wen. Before we begin, I'd like to remind you that various remarks that we make on this call that are not historical including those about our vision and business model, the company's strategic business realignment, future financial and operating results; expectations of future growth and reduction in burn rates, expectations regarding the exchange and equitization of existing notes and extension of debt maturity and future products, services and our product pipeline and the timing.
ZacksInvitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates
Invitae (NVTA) delivered earnings and revenue surprises of 38.18% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance
Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has signed exchange and financing agreements with a fund managed by Deerfield Management Company and other investors (collectively, the "Investors").
- PR Newswire
Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates
Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended December 31, 2022.
Motley FoolDown 78% in 1 Year, Is There Any Hope Left for Invitae?
With shares down by 91% in the last three years, and 78% in the last 12 months alone, Invitae (NYSE: NVTA) and its investors are bound to be feeling the burn. The genetic testing company's downward spiral led Wall Street analysts to downgrade the stock, and many are suggesting that shareholders quit their positions. Let's explore how realistic it is for Invitae to make a comeback so that you'll know whether the odds are in your favor.
Motley FoolIf You Invested $10,000 in Invitae in 2018, This Is How Much You Would Have Today
Genetic testing company Invitae (NYSE: NVTA) has a lot of long-term potential as it could help improve the quality of healthcare for people and play a big role in transforming the industry. Below, I'll look at how much a $10,000 investment in the company would be worth today, and whether you should consider buying shares today. In 2018, Invitae was coming off a year where its revenue totaled $68 million and had more than doubled the prior-year's tally of $25 million.